Audit: QRS - Muira Puama for Health & Longevity

Audit conducted on 20/08/2026 05:37 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Dose range, 4:1 ratio, 4–6 g crude equivalence, alcohol-solubility, timing, all benefit/risk tiers, contraindications, interactions, markers and cadence trace to ER lines 260–420.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“results registry-stated and still unpublished”, “though no timing study supports it”, “Side effects reported so far are mild” mirror ER hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Nitrate contraindication retained as a stop item, not downgraded to caution; benefits remain at Low/Speculative tiers.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Protocol cells come only from ER Therapeutic Protocol; gates only from Key Interactions & Contraindications; tiers only from the matching ER benefit/risk tiers.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, NCT identifiers, investigator names or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	Only generic descriptors (“uncontrolled series”, “four-herb formula”, “four-ingredient formula”), all present in the ER.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured “believable mechanism, thin record” framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	States the evidence gap plainly while giving actionable dose, form, timing and monitoring detail.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive throughout; no imperatives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Doses and cadence are reported as what studies and practice use, not as instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” in the document voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are glossed as in the ER (“myocardial infarction (heart attack)”, NYHA and Child-Pugh classes explained).
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are noun phrases; protocol subs are one to two short sentences.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for you/your.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes a reader who will source a tested single-ingredient extract and run a biomarker panel.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring panel of seven markers plus weekly qualitative tracking presumes exactly that.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “just try it” framing; adulteration hazard and biomarker work are foregrounded.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The high-tier risk is the product-category adulteration hazard, the concern specific to a self-sourcing reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears only in the canonical topic; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses “gastrointestinal upset”, “central nervous system overstimulation”, “erectile function”, “plasminogen”-derived “clotting-marker” phrasing from the ER.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 445, 491, 542, 569, 587, 615, 638, 642–644, 752 and in the tier <strong> labels.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	60 distinct data-qrs-var spans present, each exactly once: page_title, header_, at_a_glance, action_1–3_, time_1–3*, benefits, stop/caution_items, risks_, marker_1–7_*, monitoring_cadence, qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	<span website="evidence_review">, <span website="audit"> and <span website="full_review"> are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped to a QRS variable is empty; the empty benefit tiers are handled under 12.5 by hiding the span.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard extract dose”, “Preparation matters”, “Best time of day” match ER lines 315, 323, 325 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit, risk and marker labels reproduce the ER headings and biomarker names; time-cell labels are drawn from the corresponding ER benefit headings.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan returns no emoji code points; the ER’s ⚠️ Conflicted markers were dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Three protocol cells, three time cells, two tiered lists, eight and ten gate items, seven markers, six qualitative items — within the one-page budget.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Entirely inside the HTML comment; no duplicate on-page rendering.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: muira_puama_2026-0825-0159_Opus_ER.md (line 4) matches the ER’s own filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0820-0521, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (line 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (line 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: muira_puama_2026-0825-0159_Opus_QRS.html matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Muira Puama for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Muira Puama for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0820-0521 → “08/20/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 441–445: two-sided reputation, laboratory profile, absent placebo evidence, mild side effects, adulteration as dominant hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four sentences maps to a distinct sentence in the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “brain chemistry”, “blood-vessel relaxation”, “hidden prescription drugs” are plain-language renderings.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items come from the ER’s “Populations who should avoid Muira puama” list (ER lines 284–291).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Eight ER avoid-bullets → eight <li> items, one-to-one, with the nitrate absolute contraindication (ER line 260) folded into item 3.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements inside the stop_items span (lines 571–583).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing clause (“— no reproductive toxicology…”, “because of the adulteration hazard”, “— clearance is entirely uncharacterised”) is stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 90 days”, “Class III–IV (marked limitation of activity, or symptoms at rest)”, “Child-Pugh Class B or C (moderate to severe)”, “(breast, uterine, prostate)” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations, and the section is correspondingly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map to ER bullets at lines 262–280.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Ten of the ER’s eleven interaction bullets appear; nitrates are correctly omitted because they are carried as a stop item.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten discrete <li> elements (lines 590–605).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is the drug class alone; the ER’s Caution/Monitor tags, mechanisms and mitigations are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug parenthetical is retained verbatim, including the italicised Bacopa monnieri and Panax ginseng.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists eleven interactions, and the section is correspondingly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol lines 315, 323, 325 and 335.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, preparation/solvent and timing are the three decisions a reader must make before starting.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Sexual function (ER line 374), burning mouth syndrome (ER line 152) and artery dilation (ER line 158) are the only outcomes with a stated onset.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER’s Low-tier benefit ordering: sexual desire and erection, burning mouth syndrome, artery dilation.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; subs carry the ER’s caveats (8–12 week assessment window, formula-only testing, unpublished registry result).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Low and Speculative items reproduce the ER’s benefit headings at lines 142–180.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (lines 544–562).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Semicolon-separated benefit names only; no magnitudes or study detail carried across.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in either tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High or Medium benefit; both spans carry style="display: none" with no empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All four tiers reproduce the ER headings at lines 206–236.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (lines 617–632).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Risk names only; the ER’s 45.5%/47.0%/9.3% magnitudes and the ⚠️ Conflicted marker are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four risk tiers, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows reproduce the ER biomarker table at lines 402–410.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER rows present — total testosterone, free testosterone, sensitive estradiol, SHBG, ALT, hs-CRP, resting blood pressure — with ranges and rationales verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	“Blood pressure and symptoms at two weeks; full panel and questionnaire at eight weeks; then every 6–12 months for long-term use.” condenses ER line 400.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items reproduce the ER’s qualitative marker bullets at lines 414–419.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER bullets present: desire, erection quality on the IIEF, fatigue and stamina, sleep onset and waking, tension and irritability, cognitive clarity.

Issues 20/08/2026 05:37

Pass rate 100.00%. No issues found.

Issues 20/08/2026 05:31

1. 8.5 — Contraindication parentheticals dropped: The QRS drops three ER parenthetical qualifiers entirely instead of trimming them — “(heart attack)”, “(marked limitation of activity, or symptoms at rest)” for NYHA Class III–IV, and “(moderate to severe liver failure)” for Child-Pugh B/C (QRS lines 574–576, from ER lines 286–288) — removing the plain-language staging glosses a reader needs to decide whether the gate applies.

Fixes 20/08/2026 05:31

1. 8.5 — Contraindication parentheticals restored: Re-added the three dropped ER parenthetical qualifiers to the Contraindications gate — “(heart attack)” after myocardial infarction, “(marked limitation of activity, or symptoms at rest)” after NYHA Class III–IV heart failure, and “(moderate to severe)” after Child-Pugh Class B or C liver impairment. The Child-Pugh gloss was trimmed from the ER’s “moderate to severe liver failure” to fit the one-page budget without dropping it.

Issues 20/08/2026 05:26

1. 2.5 — Directive age-dose phrasing: action_1_sub (lines 456-457) states “Older adults start at 500–1,000 mg”, an unhedged instruction, where the ER Therapeutic Protocol says “Older adults … are reasonably started at the lower end (500–1,000 mg)”.

Fixes 20/08/2026 05:26

1. 2.5 — Directive age-dose phrasing: Rewrote action_1_sub from “Older adults start at 500–1,000 mg” to “Older adults are reasonably started at 500–1,000 mg”, restoring the ER’s hedged, non-directive wording.